NovoCure (NVCR) Stock Statistics & Valuation Metrics

NovoCure has a market cap or net worth of $2.06B. The enterprise value is $1.73B.

NovoCure has 111,485,634 shares outstanding. The number of shares has decreased by -2.65% in one year.

NovoCure’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -37.44%.

The current PE Ratio of NovoCure is -19.06. NovoCure’s PEG ratio is 0.95.

In the last 12 months, NovoCure had revenue of 605.22M and earned -168.63M in profits. Earnings per share was -1.56.

In the last 12 months, operating cash flow was -30.46M and capital expenditures -41.68M, giving a free cash flow of -72.14M billion.

NovoCure pays an annual dividend of ―, resulting in a dividend yield of ―

NovoCure upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.

NovoCure as a current ratio of 1.46, with Debt / Equity ratio of 24.66%

In the past 12 months, NovoCure has paid 37.47M in taxes.

NovoCure EV to EBITDA ratio is -28.68, with an EV/FCF ratio of -45.40.

NovoCure has $929.13M in cash and marketable securities with $89.25M in debt, giving a net cash position of -$839.88M billion.

Gross margin is 77.16%, with operating margin of -28.17%, and net profit margin of -27.86%.

The average price target for NovoCure is $34.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy